- Shooting death of gay man rocks New York's cradle of gay rights
- Taxes on some wealthy French top 100 pct of income: paper
- Justin Bieber, Taylor Swift big winners at Billboard Awards
- Hezbollah steps up Syria battle, Israel threatens more strikes |
- Powerful tornadoes strike in four central U.S. states |
India's Piramal sees $1.5 bln rev from florbetaben
MUMBAI, April 16 |
MUMBAI, April 16 (Reuters) - Indian drugmaker Piramal Healthcare sees revenue potential of $1.5 billion from its newly acquired florbetaben molecule, which could be used to treat Alzheimer's disease, its chairman, Ajay Piramal, said on Monday.
The company will file for U.S. approval of the treatment in late 2012, Piramal added.
Piramal agreed to buy a research and development portfolio from Germany's Bayer AG in a deal that gives the Indian drugmaker commercial and development rights to florbetaben. (Reporting by Kaustubh Kulkarni; Editing by Aradhana Aravindan)
- Tweet this
- Share this
- Digg this